Drug Profile
Latrodectus antivenin - Instituto Bioclon/Rare Disease Therapeutics
Alternative Names: Analatro; ANAWIDOW; Antivenin Latrodectus equine immune F(ab)2 - RDT/Bioclon; Aracmyn; Black widow spider antivenin - RDT/Bioclon; Black widow spider antivenom - RDT/Bioclon; Latrodectus immune F(ab’)2 antivenom - Instituto Bioclon/Rare disease therapeutics; Spider venom antiserum - RDT/BioclonLatest Information Update: 07 Dec 2018
Price :
$50
*
At a glance
- Originator Instituto Bioclon
- Developer Instituto Bioclon; Rare Disease Therapeutics
- Class Antibodies; Antivenins
- Mechanism of Action Spider venom inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Spider venom poisoning
Most Recent Events
- 07 Dec 2018 Launched for Spider venom poisoning in USA before November 2018 (IV) (Rare disease therapeutics website, November 2018)
- 12 Aug 2005 Phase-II clinical trials in Spider venom poisoning in USA (unspecified route)